Haemonetics Corporation (HAE)
| Previous close | 90.09 |
| Open | 90.79 |
| Bid | 89.25 x 800 |
| Ask | 89.57 x 1300 |
| Day's range | 88.88 - 91.00 |
| 52-week range | 70.74 - 97.97 |
| Volume | |
| Avg. volume | 473,403 |
| Market cap | 4.524B |
| Beta (5Y monthly) | 0.33 |
| PE ratio (TTM) | 38.85 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Haemonetics Prices Upsized Private Placement of $600 Million Convertible Senior Notes
Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $600,000,000 aggregate principal amount of 2.50% Convertible Senior Notes due 2029 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering size was increased from the previously announced offering size of $525,000,000 aggregate principal amount of notes. The offerin
- PR Newswire
Haemonetics Announces Proposed Convertible Senior Notes Offering
Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced its intention to offer, subject to market and other conditions, $525,000,000 aggregate principal amount of Convertible Senior Notes due 2029 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Haemonetics also expects to grant the initial purchasers of the notes an option to purchase up to an additional $
- PR Newswire
Haemonetics 4th Quarter and Fiscal Year 2024 Earnings Release Available on Investor Relations Website
Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter and fiscal year 2024, which ended March 30, 2024, are available on its Investor Relations website.
